- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00549016
Clinical Study of Aneurysm Exclusion (EndoMed)
Clinical Study of Aneurysm Exclusion Using PTFE Encapsulation of Nitinol Stents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Arizona Heart Institute is respectfully submitting this protocol for a feasibility study utilizing the endoluminal grafts constructed of PTFE encapsulated nitinol stents. The study is intended to evaluate the use of this unique device in the treatment of aortic aneurysmal disease. The stent graft is made by laminating a PTFE "jacket" around nitinol stents which act as structural and fixation supports. Both materials have an extensive history of use in various types of implanted devices. CT scans and angiography or 3D computer imaging, and possibly IVUS imaging will be used to choose the sites for placement of the devices and to assure precise deployment.
In comparison to the conventional surgical approach, endoluminal stent-graft techniques for repair of abdominal aortic aneurysms (AAAs) offer the advantages of a minimally invasive procedure with lower morbidity and perhaps cost reduction. The Arizona Heart Institute has a long history in the area of endoluminal grafting for treatment of aneurysms and occlusive disease. Endoluminal sleeves principally using ePTFE and both stainless steel and nitinol stent structures have been studied using commercially available materials customized for particular pathologic situations. As the technology advances however, sophisticated engineering beyond the capabilities of our institution was required.
The proposed project originates because of the potential to escalate the combination of ePTFE and stents to a higher level of performance in aneurysm exclusion procedures. Current data reflect several deficiencies in approved exclusion devices. Migration, types I, II and III endoleaks and continual aneurysm expansion are clear predictors for potential ruptures. Increased complications associated with the initial peri-procedural deployment as devices are released on a broader scale have been observed. In order to address these problems, the Arizona Heart Institute has engaged EndoMed engineering to design the endoluminal graft to repair abdominal aortic aneurysms. We believe this will result in a positive step forward in the technology to exclude aneurysmal disease less invasively.
The endoluminal stent-graft is composed of multiple nitinol stents which are encapsulated in expanded Polytetrafluoroethylene (ePTFE). The stents are composed of a Z-shaped, performed nitinol wire, which is crimped together with a stainless steel sleeve to form the circular frame of the graft. This frame is then encapsulated between two thin sheets of laminated PTFE. The proximal end of the endoluminal stent-graft is made in two configurations. One is a completely encapsulated graft where the PTFE covers the entire device. The other has an open stent segment (bare wire configuration) that allows the open stent region of the graft to be placed across the orifice of the renal, mesenteric, or internal iliac arteries without obstructing antegrade blood flow. The device will be available in a straight tube, aortomonoiliac or bifurcated design.
Once the endoluminal stent graft is built, a 4 French guidewire dilator is placed through the center of the graft and the assembly is compressed into a high density polyethylene (HDPE) cartridge for ease of intraluminal delivery. The endoluminal stent-graft is then placed in two Tyvek pouches and sterilized using Hydrogen Peroxide.
Subjects will undergo an evaluation of the PTFE encapsulation of Nitinol stents to provide data on the device's feasibility for therapeutic clinical use. Follow-up will be completed at 1, 6, 12, 24, 36, 48, and 60 months. Subject evaluation at 1 month will include a Complete History and Physical, Bilateral ABIs, Abdominal Duplex Ultrasound, and a KUB X-ray (4 views). Subject evaluation at 6 months will also include a Complete History and Physical, Bilateral ABIs, Abdominal Duplex Ultrasound, KUB X-ray (4 views), and based on the duplex ultrasound an Abdominal CT scan with and without IV contrast 2.5 mm and Labs (BUN/Creatinine). Subject evaluation at 12, 24, 36, 48, and 60 months will include a Complete History and Physical, Bilateral ABIs, Abdominal CT scan with and without IV contrast 2.5 mm, Abdominal Duplex Ultrasound, KUB X-ray (4 views), and Labs (BUN/Creatinine).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Recruiting
- Arizona Heart Institute
-
Sub-Investigator:
- Julo Rodriguez-Lopez, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aneurysm diameter ≥ 4.0 cm; or aneurysm diameter ≤ 4.0 cm which has exhibited rapid expansion; or aneurysms with saccular configuration where potential for rupture is increased; or aneurysms which have exhibited dissection and there is potential for rupture or compromised flow to vital structures; or symptomatic leaking or ruptured aneurysms.
- Vessels proximal and distal to the lesion must be capable of accommodating the device.
- The access artery diameter and profile of the artery must be capable of the device delivery.
- Patients must be ASA III or higher.
- Informed consent must be obtainable.
- Patients must be willing and able to comply with the follow-up regime.
- Patients with neck grades as follow:
- Grade I: Length of Proximal Neck ≥ 1.5 cm and Distal Neck ≥ 1.0 cm
- Grade II: Length of Proximal Neck ≥ 1.5 cm, but Distal Neck < 1.0 cm without obvious iliac aneurysms, or aneurysm extends into or is associated with iliac aneurysms.
- Grade III: Length of Proximal Neck < 1.5 cm and Distal Neck ≥ 1.0 cm
- Grade IV: Length of Proximal Neck < 1.5 cm and Distal Neck < 1.0 cm or the involvement as in Grade II.
Exclusion Criteria:
- A proximal neck less than 0.5 cm in length.
- Arterial diameter larger than 40 mm at the proximal or distal landing zones.
- Iliac diameter less than 6 mm (following balloon angioplasty as needed).
- The inferior mesenteric artery is indispensable.
- Patients under the age of 18.
- Pregnant or lactating women.
- Patients with allergy to any of the device materials.
- Patients with uncorrectable coagulopathy or bleeding disorders.
- Patients for whom contrast medium or anticoagulation drugs are contraindicated.
- Patients with active systemic or localized groin infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices.
The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Technical success in the deployment and placement of the endoluminal graft to the aneurysmal site.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Acute success when the endoluminal graft excludes the aneurysm and maintain patency without endoleaks, migration or rupture.
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- G020035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysm
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
IRCCS San RaffaeleCompletedAneurysm Thoracic | Aneurysm Abdominal | Renal AneurysmUnited States, France, Italy, United Kingdom, Germany, Spain, Denmark, Sweden
-
JOTEC GmbHRecruiting
-
The Christ HospitalMedtronicRecruiting
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
CEVARIIUniversity of Colorado, Denver; University of Copenhagen; University of Iowa; University... and other collaboratorsEnrolling by invitationComplex EVAR in Inflammatory and Infective Abdominal and Thoracoabdominal Aortic Aneurysms (CEVARII)Abdominal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Aneurysm, Infected | Inflammatory Abdominal Aortic Aneurysm | Aneurysm, MycoticUnited States
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
Petrovsky National Research Centre of SurgeryRecruitingAorta Abdominalis; Aneurysm | Aorta Thoracic; AneurysmRussian Federation
-
Cook Research IncorporatedCompletedAbdominal Aortic Aneurysm (AAA) | Aorto-iliac Aneurysm | Juxtarenal AneurysmUnited States
Clinical Trials on PTPE Encapsulation of Nitinol Stents
-
Nantes University HospitalCompletedAtherosclerotic Lesions of the Common Femoral ArteryFrance
-
University of PatrasUnknownChronic Total Occlusion of Artery of the ExtremitiesGreece, Italy, United Kingdom
-
Medi-Tate Ltd.CompletedBenign Prostate Hyperplasia | Bladder Neck ObstructionIsrael
-
Uppsala University HospitalBeta-O2 Technologies Ltd.Active, not recruiting
-
pfm medical agAix ScientificsCompletedHeart Septal Defects, VentricularGermany, Israel
-
Leonardo Bolognese, MDCompleted
-
Vienna General HospitalCompletedPeripheral Vascular Diseases | Intermittent Claudication | AngioplastyAustria
-
Hexacath, FranceUnknownAcute Coronary Syndrome | Stable Angina | Silent Myocardial InfarctionFrance
-
University of FreiburgCompletedCoronary Artery DiseaseSwitzerland
-
Group of Research in Minimally Invasive TechniquesCompletedBiliary Tract Diseases | Stenosis | Stents | Biliary Tract | Follow-Up StudiesSpain